After numerous successful trials in the model, the team sought to demonstrate what the microrobot could achieve under real clinical conditions. First, they were able to demonstrate in pigs that all three navigation methods worked and that the microrobot remains clearly visible throughout the entire procedure. The investigators then navigated microrobots through the cerebral fluid of a sheep.

“This complex anatomical environment has enormous potential for further therapeutic interventions, which is why we were so excited that the microrobot was able to find its way in this environment too,” Landers noted. “In vivo experiments conducted with an ovine model demonstrated the platform’s ability to operate within anatomically constrained regions of the central nervous system,” the investigators stated in their paper. “Furthermore, in a porcine model, all locomotion strategies were validated under clinical conditions, confirming precise microrobot navigation within the cerebrovascular system and highlighting the system’s compatibility with versatile in vivo environments.”

In addition to treating thrombosis, these new microrobots could also be used for localized infections or tumors. At every stage of development, the research team has remained focused on their goal, which is to ensure that everything they create is ready for use in operating theaters as soon as possible. The next goal is to look at human clinical trials. “The use of materials that have been FDA approved for other intravascular applications, coupled with the modular design of the robotic platform, should simplify translation and adaptability to a range of clinical workflows,” the authors concluded. Speaking about what motivates the whole team, Landers said, “Doctors are already doing an incredible job in hospitals. What drives us is the knowledge that we have a technology that enables us to help patients faster and more effectively and to give them new hope through innovative therapies.”

Biology needs the same kind of substrate. Without it, we are still guessing. With it, discovery starts to look predictable by design.

Drug development still leans on animal models and small patient cohorts to make billion-dollar bets. Those proxies teach us something, but they do not teach how a molecule behaves across the complexity of human biology. That is why nine out of ten drugs that succeed in animals fail in human clinical trials.

Biology needs an environment that gives intelligence the same systematic feedback that data centers gave to computation. That is what biological data centers provide. Robotic systems that sustain tens of thousands of standardized human tissues at once. Tissues that are vascularized and immune competent, clinically indistinguishable from patient biopsies under blinded review. Tissues that can be dosed, that bleed, that heal.

UC San Diego researchers have settled a decades-long debate surrounding the role of the first Crohn’s disease gene to be associated with a heightened risk for developing the auto-immune condition.